Inovio's Latest COVID Vaccine Results: Too Little, Too Late?

Inovio Pharmaceuticals (NASDAQ: INO) recently reported encouraging results from a phase 2 study of its COVID-19 vaccine candidate INO-4800. However, the company lags well behind the current leaders in the COVID-19 vaccine market. In this Motley Fool Live video recorded on May 12, Motley Fool contributors Keith Speights and Brian Orelli discuss Inovio's latest clinical results.

Continue reading

Source Fool.com